We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Bioanalytical Systems Inc | NASDAQ:BASI | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 16.44 | 15.65 | 16.65 | 0 | 01:00:00 |
The AAALAC International Council on Accreditation commended Inotiv’s West Lafayette facility for excellent institutional support, specifically noting financial support for facilities, infrastructure, continuing education and development of staff, an engaged Institutional Animal Care and Use Committee (IACUC), and exceptionally well-maintained facilities.
“We choose to make investments such as those to our West Lafayette facility because they allow us to provide the speed and quality that our clients deserve, while at the same time promoting the highest possible standards of care and service,” said Company President and Chief Executive Officer Robert Leasure, Jr. “We take pride in all of our facilities being AAALAC accredited, even those where it would not be required. We hold ourselves to that high standard.”
The West Lafayette facility showcases advanced in vivo capabilities, purpose-built to characterize pharmacologic and toxicologic parameters of drug candidates. The vivarium utilizes state of-the-art equipment including the Company’s Culex Automated Pharmacology System and Empis System.
About the Company
Bioanalytical Systems, Inc., doing business as Inotiv, is a pharmaceutical development company providing contract research services and monitoring instruments to emerging pharmaceutical companies and the world's leading drug development companies and medical research organizations. The Company focuses on developing innovative services supporting its clients’ discovery and development objectives for improved decision-making and accelerated goal attainment. The Company’s products focus on increasing efficiency, improving data, and reducing the cost of taking new drugs to market. Visit inotivco.com for more information about the Company.
This release may contain forward-looking statements that are subject to risks and uncertainties including, but not limited to, risks and uncertainties related to changes in the market and demand for our products and services, the development, marketing and sales of products and services, changes in technology, industry and regulatory standards, the timing of acquisitions and the successful closing, integration and business and financial impact thereof, the impact of the COVID-19 pandemic on the economy, demand for our services and products and our operations, including the measures taken by governmental authorities to address the pandemic, which may precipitate or exacerbate other risks and/or uncertainties and various other market and operating risks, including those detailed in the Company's filings with the U.S. Securities and Exchange Commission.
Company Contact | Investor Relations |
Bioanalytical Systems, Inc., dba Inotiv | The Equity Group Inc. |
Beth A. Taylor, Chief Financial Officer | Kalle Ahl, CFA |
(765) 497-8381 | (212) 836-9614 |
btaylor@inotivco.com | kahl@equityny.com |
Devin Sullivan | |
(212) 836-9608 | |
dsullivan@equityny.com |
1 Year Bioanalytical Systems Chart |
1 Month Bioanalytical Systems Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions